Tebentafusp – September 2023

• Brand names:
  • Kimmtrak®
• Pharmaceutical Company:
  • Synevi Pty Limited
• Condition/Indication: Advanced (unresectable or metastatic) human leukocyte antigen (HLA)-A*02:01-positive uveal melanoma
• Meeting Date: September 2023
• Public Summary Document (PSD) March 2023 September 2023 PBAC Meetings - (PDF 1.1MB)
• Public Summary Document (PSD) March 2023 September 2023 PBAC Meetings - (Word 356KB)

Related Public Summary Documents

Tebentafusp – March 2023